M. Torrens

2 papers in the library · 67 citations · publishing 2012-2016

Papers

Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT)

PLoS One October 24, 2012 Ricardo Pardo‐lozano, M. Farré, Samanta Yubero‐lahoz et al. 67 citations

A single oral weight-adjusted dose of MDMA (1.4 mg/kg) produced similar plasma concentrations and positive subjective effects in healthy recreational users regardless of gender or CYP2D6 and COMT genotypes. Female subjects experienced more intense physiological effects (increased heart rate and oral temperature) and negative effects (dizziness, sedation, depression, psychotic symptoms). Genotypes of COMT val158met or 5-HTTLPR with high functionality led to greater cardiovascular effects, while low-functionality genotypes were linked to negative subjective effects. The contribution of MDMA pharmacokinetics to gender differences in drug effects appears negligible; instead, 5-HTTLPR and COMT val158met genotypes play a major role.

DOI: 10.1371/journal.pone.0047599 Full text Medicine Psychology

25I-NBOMe: The legal LSD

European Psychiatry March 1, 2016 I. Ezquiaga, M. Grifell, L. Galindo et al.

Between 2009 and 2015, 56 samples of the potent hallucinogen 25I-NBOMe were identified among 21,198 drug samples submitted to a Spanish harm-reduction service. Most samples (42.8%) were sold as LSD, while only 21.4% were sold as 25I-NBOMe itself; others were misrepresented as related substances or even gummy bears. All 25I-NBOMe samples appeared after 2012, with a peak in 2013. The substance has high affinity for serotonin 5HT2a receptors and has been linked to toxicity. The authors call for more research and for physicians to be aware of novel psychoactive substances and their clinical differences.

DOI: 10.1016/j.eurpsy.2016.01.006